Ignite Creation Date:
2025-12-24 @ 10:02 PM
Ignite Modification Date:
2025-12-25 @ 7:38 PM
Study NCT ID:
NCT00334932
Status:
UNKNOWN
Last Update Posted:
2014-01-10
First Post:
2006-06-07
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
Sponsor:
Herbert Irving Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-02
Start Date Type:
None
Primary Completion Date:
2010-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2006-06-07
First Submit QC Date:
None
Study First Post Date:
2006-06-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-01-09
Last Update Post Date:
2014-01-10
Last Update Post Date Type:
ESTIMATED